Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 6/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27681175 | 0.94 | REN (0.48) | RENBACE1ALDH1A1NPC1RAB9A | |
| Acetic Acid SCHEMBL4347586 | 0.93 | REN (0.47) | RENBACE1ALDH1A1NPC1RAB9A | |
| SCHEMBL29700371 | 0.91 | CARM1 (0.42) | RENBACE1ALDH1A1CARM1PRMT6 | |
| SCHEMBL27775729 | 0.90 | CARM1 (0.41) | RENBACE1ALDH1A1CARM1PRMT6 | |
| Acetic Acid SCHEMBL27464542 | 0.77 | REN (0.41) | RENBACE1NPC1RAB9ACARM1 | |
| Acetic Acid SCHEMBL27517314 | 0.75 | CARM1 (0.58) | RENCARM1PRMT6PRMT8TMEM97 | |
| Acetic Acid SCHEMBL28847873 | 0.75 | REN (0.49) | RENBACE1NPC1RAB9ACARM1 | |
| SCHEMBL1703434 | 0.74 | CARM1 (0.45) | CARM1PRMT6PRMT8SIGMAR1 | |
| Acetic Acid SCHEMBL28850624 | 0.72 | REN (0.39) | RENBACE1NPC1RAB9ACA12 | |
| Acetic Acid SCHEMBL31201831 | 0.71 | KMT2A (0.52) | ALDH1A1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2053968-A2 | METHODS FOR LYMPH SYSTEM IMAGING | EPIX Pharmaceuticals, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008022263-A2 | METHODS FOR LYMPH SYSTEM IMAGING | EPIX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044358-A1 | METHODS FOR LYMPH SYSTEM IMAGING | LANTHEUS MEDICAL IMAGING, INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044358-A1 | METHODS FOR LYMPH SYSTEM IMAGING | LTA, CCR3, ABHD12 | REN 3763/4885BACE1 4864/4885ALDH1A1 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.